Insider · CIK 0001683607
Bonnie L Bassler
director
Files at REGN (REGENERON PHARMACEUTICALS, INC.), CDTX (Cidara Therapeutics, Inc.), RPRX (Royalty Pharma plc). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | RPRX Royalty Pharma plc | AGrant or award Class A Ordinary Shares | +642 | $58.41 | $37k | 79,823 | 12 d ago |
| Sep 30, 2025 | RPRX Royalty Pharma plc | AGrant or award Class A Ordinary Shares | +1,047 | $35.79 | $37k | 72,165 | Sep 30, 2025 |
| Jun 30, 2025 | RPRX Royalty Pharma plc | AGrant or award Class A Ordinary Shares | +1,064 | $35.24 | $37k | 71,118 | Jun 30, 2025 |
| Jun 18, 2025 | CDTX Cidara Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +11,100 | $0.00 | $0 | 11,100 | Jun 18, 2025 |
| May 13, 2025 | RPRX Royalty Pharma plc | AGrant or award Class A Ordinary Shares | +7,614 | $0.00 | $0 | 70,054 | May 14, 2025 |
| Mar 31, 2025 | RPRX Royalty Pharma plc | AGrant or award Class A Ordinary Shares | +1,141 | $32.87 | $37k | 62,440 | Apr 1, 2025 |
| Jan 2, 2025 | REGN REGENERON PHARMACEUTICALS, INC. | AGrant or award Common Stock | +166 | $0.00 | $0 | 1,548 | Jan 6, 2025 |
| Jan 2, 2025 | REGN REGENERON PHARMACEUTICALS, INC. | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +1,958 | $0.00 | $0 | 1,958 | Jan 6, 2025 |
| Dec 31, 2024 | RPRX Royalty Pharma plc | AGrant or award Class A Ordinary Shares | +1,503 | $24.94 | $37k | 61,299 | Jan 2, 2025 |
| Dec 17, 2024 | CDTX Cidara Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +16,000 | $0.00 | $0 | 16,000 | Dec 19, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.